When gold surged past $4,550 an ounce on December 29, it did more than just notch a record. It confirmed that 2025 would be remembered as the year precious metals entered a new regime, a supercycle.

The Ministry of Finance has decided to keep interest rates on small savings schemes unchanged for the January–March 2026 quarter. The rates will continue at the levels announced on September 30, 2025, ...

Realty Income offers the highest yield at 5.62% and pays dividends monthly instead of quarterly. AbbVie raised its dividend 5.5% to $6.92 annually with revenue up 9.1% to $15.8B. Procter & Gamble ...

On the heels of a big beat with its latest quarterly results, Nvidia CEO Jensen Huang said sales of the company's Blackwell offering are "off the charts." Meanwhile, graphics processing units for the ...

Both stocks trade at once-in-a-decade low valuations and have all-time high dividend yields. Each company leads in its niche, but both are battling through minor challenges. Despite rocky results ...

WALL, N.J.--(BUSINESS WIRE)--The board of directors (the “Board”) of New Jersey Resources Corporation (NYSE: NJR) unanimously declared a quarterly dividend on its common stock of $0.475 per share. The ...

Bitcoin's surge to fresh all-time highs has some investors thinking about what the next key levels are for Bitcoin. Michael Saylor thinks the party will keep going, and there's the potential for ...

Cars parked in the Towers parking lot at the University of Connecticut. Parking has increasingly become an issue as the university has overenrolled. Photo courtesy of Colin Mitchell/The Daily Campus ...

The new Premix facility in North Carolina with carbon black silos visible on the outside. Premix's new facility in North Carolina features end-to-end automation to provide real-time monitoring of ...

Artificial intelligence is currently running on a one-lane CapEx highway that is capacity-constrained. Hyperscaler cloud providers are the largest contributor to the momentum and as such, investors ...

Novo Nordisk's shares plunged more than 20% Tuesday, after the company cut the forecast for its flagship obesity drug. Before the markets opened, the company announced that sales of its obesity ...